Big pharma’s approach to digital medicine

November 24, 2016 Christoph Graener

The convergence of new technologies and therapies is reshaping the entire landscape of healthcare. Panelists share their perspectives on how therapeutic applications, clinical trials, drug delivery, and adherence will be altered by digital medicine’s influence.

Moderator: Nima Jokilaakso – Swecare

  • Alexandra Eberhard – Signal Analytics
  • Tracy Mayne – Purdue Pharma L.P.
  • Peter Neubeck – ExB Labs
  • Matthew Owens – Novartis

Previous Article
Immunotherapies: Partnership models driving cures

While new immunotherapies have entered the market and there are many exciting products in development, the ...

Next Article
Leveraging real-world evidence and insights to build value in emerging biopharma programs
Leveraging real-world evidence and insights to build value in emerging biopharma programs

No one saw it coming. In October 2016 Quintiles and IMS Health formally merged to become the world's larges...